ProMIS Neurosciences Appoints James Kupiec, MD as Chief Medical Officer
Dr. Kupiec to leverage neurodegenerative experience from prior senior positions at Pfizer and Sanofi-Synthelabo
TORONTO and CAMBRIDGE, MA, Sept. 13, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of James Kupiec, MD, to the position of Chief Medical Officer. In this newly created role, reporting to both the Executive Chairman and CEO, Dr. Kupiec will lead ProMIS' clinical development programs, in particular the initiation of clinical trials of PMN310 for the treatment of Alzheimer's disease (AD) in the second half of 2019.
"We are very pleased to welcome Dr. Kupiec to our senior management team," said ProMIS Executive Chairman, Eugene Williams. "Jim's expertise and experience as an accomplished leader of clinical development programs in Alzheimer's disease and other neurodegenerative disorders will be a great source of strength for ProMIS. He will not only provide outstanding clinical trial leadership but will also play a significant role in interaction with regulatory authorities, key neuroscience opinion leaders and potential pharmaceutical partners."
Dr. Kupiec is a physician-scientist with over two decades of broad, hands-on experience in translational, early- and late-stage neuroscience drug development in the pharmaceutical industry.
"I am thrilled to join the ProMIS leadership team at this critical stage," said Dr. Kupiec. "ProMIS' innovative approach selectively targeting toxic oligomers for treatment of neurodegenerative disorders is unique and provides a real opportunity for transformative, novel therapies. I am delighted to contribute to the advancement of the ProMIS clinical pipeline."
Dr. Kupiec most recently served as VP, Global Clinical Leader for Parkinson's Disease, and Clinical Head of the Neuroscience Research Unit in Cambridge for Pfizer, Inc. He joined Pfizer in 2000 after seven years at Sanofi-Synthelabo, and two years with Ciba-Geigy Pharmaceuticals. During his career at Pfizer, he had extensive governance, business development, alliance and leadership responsibilities. Much of his work during the last decade has focused on developing potential disease modifying and symptomatic therapies for Alzheimer's disease and other neurodegenerative disorders, including monoclonal antibodies. As project leader and Clinical Head, Dr. Kupiec created and implemented global drug development strategies, met with worldwide regulatory authorities, and chaired numerous joint development committees with other pharmaceutical companies.
He earned his BS with Honors in Biochemistry at Stony Brook University and his MD from the Albert Einstein College of Medicine. He completed his residency training at the Strong Memorial Hospital, University of Rochester School of Medicine, and is certified by the American Board of Internal Medicine.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform — ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information please consult the Company's website at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including about the timing and completion of the Offering, the receipt of TSX approval and the expected use of proceeds from the Offering. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE ProMIS Neurosciences Inc.
For media inquiries, please contact: Shanti Skiffington, [email protected], Tel. 617 921-0808; For Investor Relations please contact: Alpine Equity Advisors, Nicholas Rigopulos, President, [email protected], Tel. 617 901-0785; Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, [email protected]
Share this article